Company / Operating Cash Flow
Acadia Pharmaceuticals Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
$109.8M
FY2025
5-year range
-$125.7M / $157.7M
FY2021-FY2025
Trend
-30.4%
vs FY2024
Sector context
#53 of 216
Health Care
What the data says
Acadia Pharmaceuticals's operating cash flow of $110M is higher than 75% of companies in the Health Care sector (FY2025). Improved from $17M to $110M over the past 2 years.
Based on SEC 10-K filings.
$110M in FY2025. Top quartile in the Health Care sector.
Improved from $17M to $110M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 25% in Health CareTop 25% of 216This company $109.8M Sector average $659.0M
▼
-83.3% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow decreased 30.4% year-over-year.
- Ranks #53 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2024.
- Lowest operating cash flow in the period was in FY2017.
Company context
Key Data Points
- Strong profit margin: 24.9%
- Low earnings quality (accrual-heavy earnings)
- Strong return on equity: 28.5%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $109.8M | -30.4% |
| FY2024 | $157.7M | +844.3% |
| FY2023 | $16.7M | +114.6% |
| FY2022 | -$114.0M | +9.3% |
| FY2021 | -$125.7M | +7.7% |
| FY2020 | -$136.2M | +9.9% |
| FY2019 | -$151.1M | +9.8% |
| FY2018 | -$167.5M | +23.1% |
| FY2017 | -$217.8M | -4.5% |
| FY2016 | -$208.4M | -71.1% |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026